Table 1.
Patient characteristics
| Patients (n = 8) | |
|---|---|
| Age (years) | 67 ± 2 |
| Female (n, %) | 3, 37.5% |
| Male (n, %) | 5, 62.5% |
| BMI (kg/m2) | 24.3 ± 1.4 |
| Weight loss over the last 6 months (%) | 13.0 ± 2.2 |
| L3‐skeletal muscle index (cm2/m2) | 45.1 ± 2.5 |
| L3‐visceral adipose tissue index (cm2/m2) | 58.1 ± 16.7 |
| L3‐subcutaneous adipose tissue index (cm2/m2) | 57.3 ± 11.5 |
| Type of surgery (n, %) | |
| Pylorus‐preserving pancreaticoduodenectomy | 6, 75% |
| Double bypass | 2, 25% |
| Histopathological diagnosis (n, %) | |
| Pancreatic adenocarcinoma | 5, 62.5% |
| Ampullary carcinoma | 1, 12.5% |
| Intrapancreatic cholangiocarcinoma | 2, 25% |
| PG‐SGA score | 15.4 ± 2.0 |
| MUST score | 1.8 ± 0.2 |
| Triceps skinfold (mm) | 12.8 ± 1.7 |
| Handgrip strength (kg) | 30.4 ± 2.4 |
| C‐reactive protein (mg/L) | 5.9 ± 1.3 |
| Albumin (g/L) | 30.7 ± 1.3 |
| Interleukin‐1β (pg/mL) | 5.1 ± 0.8 |
| Interleukin‐6 (pg/mL) | 13.1 ± 9.1 |
| TNF‐α (pg/mL) | Not detecteda |
Data are presented as mean ± standard error of the mean. BMI, body mass index; MUST, malnutrition universal screening tool; PG‐SGA, patient generated selective global assessment; TNF‐α, tumour necrosis factor‐α.
a
Plasma concentrations <2 pg/mL for all patients.